Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.
The decision to withdraw the pending applications was based on an intial review of data from the phase 3 UNITY-CLL trial.
Chronic lymphocytic leukemia (CLL) is a chronic incurable mature B-cell neoplasm that often does not require immediate treatment; however, when patients experience symptoms, such as anemia, cytopenias, or bulky lymphadenopathy, therapy is required. During a presentation at the 2022 Oncology Nurse Advisor Summit, Laura J. Zitella, MS, RN, ACNP-BC, AOCN, an associate clinical professor at…
Patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine than to the Pfizer-BioNTech vaccine.
Researchers sought to determine whether adding venetoclax to R-EPOCH would induce durable responses in patients with Richter syndrome.
Researchers sought to determine whether adding obinutuzumab to ibrutinib for patients with CLL would permit earlier ibrutinib discontinuation.
Researchers are working towards developing CAR-T therapy to provide longer and more durable responses for patients with CLL.
Researchers sought to determine whether a third dose of the BNT162b2 mRNA vaccine against COVID-19 may induce an antibody response in patients with CLL or SLL.
A retrospective review of data from patients with CLL demonstrated varied adherence to guidelines for ramp up initiation and laboratory monitoring.
Researchers sought to determine whether age impacts survival in patients with CLL undergoing treatment with ibrutinib.
